A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
By M. Westphal, D. Hilt, E. Bortey, P. Delavault, R. Olivares, P. Warnke, I. Whittle, J. Jääskeläinen, Z. Ram. Neuro-Oncology, 2003
1,318 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/3e6906a4157fb27e907a8a27da0d088da8512561
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- R. Stupp
- Michael Weller
- M. Brada
- M. Bent
- J. Tonn
- S. Taillibert
- M. Hegi
- A. Kanner
Citations in the corpus
- Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme (2006, unknown): “[7–11].”
- High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, methodology): “Implantation of chemotherapy-impregnated wafers (carmustine polymers) into the resection cavity before radiotherapy has been shown to marginally improve median survival compared with radiotherapy alone [II, B] [28]; however, no prospective data are available when compared with current standard TMZ/ ”
- Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. (2015, background): “Another direct local delivery approach is the use of gliadel wafers, which are biodegradable polymer wafers loaded with a chemotherapeutic agent implanted into the brain or tumor cavity at the time of surgery (Brem et al., 1995; Cao and Schoichet, 1999; Groothuis, 2000; Westphal et al., 2003).”
- Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. (2012, background): “Developed in the early 1980's by Langer and Brem, this technology has been reviewed from its chemistry and mechanistic aspects of drug release to its performance across multiple clinical trials [58-60].”
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial (2017, background): “Time from last day of radiation treatment to randomization, median (range), d 37 (15-128) 36 (15-70)”